Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II VEGFR1/VEGFR2 peptide vaccine study in primary malignant glioma
jRCTs031180170Phase 2Recruiting
- Start
- Sep 2014
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VEGFR1 peptide vaccine and incomplete freund's adjuvant in malignant glioma. Primary endpoints: Safety and Overall survival. Started Sep 2014; status: recruiting.
02
Drugs
VEGFR1 peptide vaccineincomplete freund's adjuvant
03
Conditions
malignant glioma
Beyond the preview
Go deeper on jRCTs031180170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180170.